公开(公告)号：WO2017136400A1

公开(公告)日：2017-08-10

申请号：PCT/US2017/015960

申请日：2017-02-01

Applicant: STC. UNM

Inventor： HALL, Pamela ,  CHACKERIAN, Bryce ,  PEABODY, David, S. ,  DALY, Seth, Michael ,  ELMORE, Brad ,  TRIPLETT, Kathleen

IPC: A61K39/085 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/085 ,  A61K2039/5258 ,  C12N2795/18123

Abstract: The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.

Abstract translation: 本发明涉及经改造以呈递来自金黄色葡萄球菌（SA）的表位的病毒样颗粒（VLP），优选自体诱导肽（AIP），其调节该病原体中的群体感应依赖性毒力 ，或来自SA毒素和白细胞杀伤素的表位。 这些VLP可用于提供免疫原性组合物和有效疫苗。 在SA皮肤坏死的小鼠模型中，接种含AIP的VLP或含SA毒素的VLP诱导保护性免疫以限制SA感染的发病机理并促进细菌清除。

公开(公告)号：WO2016154522A1

公开(公告)日：2016-09-29

申请号：PCT/US2016/024174

申请日：2016-03-25

Applicant: STC. UNM ,  BHASKAR, Kiran ,  MAPHIS, Nicole ,  PEABODY, David, S. ,  CHACKERIAN, Bryce ,  PEABODY, Julianne ,  CROSSEY, Erin

Inventor： BHASKAR, Kiran ,  MAPHIS, Nicole ,  PEABODY, David, S. ,  CHACKERIAN, Bryce ,  PEABODY, Julianne ,  CROSSEY, Erin

IPC: A61K39/00 ,  A61P25/00 ,  A61P25/16 ,  C12N15/12 ,  C12N15/63

CPC classification number: A61K39/0007 ,  A01K67/0278 ,  A01K2217/056 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0312 ,  A01K2267/0318 ,  A01K2267/0368 ,  A61K2039/5258 ,  A61K2039/575 ,  C12N7/00 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18171

Abstract: This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.

Abstract translation: 本公开一方面描述了有效治疗和/或诊断tau病变的免疫原，以及涉及这些免疫原的免疫治疗组合物和方法。 通常，免疫原包括与至少一部分抗原呈递组分连接的抗原呈递组分和与微管相关的tau蛋白（MAPT）组分。 本公开在另一方面描述了转基因小鼠。 通常，转基因小鼠具有具有编码人微管相关蛋白tau（MAPT）的多核苷酸的脑细胞。 多核苷酸进一步显示至少部分内源小鼠MAPT的缺失。 转基因小鼠还包括编码骨髓分化原发性反应基因88（MyD88）的多核苷酸的前脑神经元特异性缺失。 在另一方面，本公开描述了生产转基因小鼠的方法。